特发性炎性肌病患者利妥昔单抗治疗后外周血B细胞亚群微小残留病流式细胞检测:单中心回顾性队列研究
这项单中心回顾性队列纳入44例接受利妥昔单抗治疗的特发性炎性肌病患者,用高灵敏度流式细胞术(HSFC)检测B细胞亚群。结果显示,第2周记忆B细胞和浆母细胞完全清除与临床应答相关,而传统流式 cutoff 无此关联。
要点
- 第2周浆母细胞完全清除者应答率更高(94% vs 31%)。
- 记忆B细胞和浆母细胞清除与应答相关,传统流式 cutoff 无关联。
核心结论
- 基于HSFC的早期完全B细胞清除与利妥昔单抗临床应答相关,传统流式细胞术 cutoff 未显示关联。
研究设计与样本
- 单中心回顾性队列研究,纳入44例符合ACR/EULAR分类标准的成人特发性炎性肌病患者,在首次利妥昔单抗输注前和第2周进行HSFC检测。
主要发现
- 传统流式细胞术 cutoff 与应答无关联。
关键数值与推荐
- 临床应答定义为输注后4-6个月首次随访时2016年ACR-EULAR总改善评分至少中度改善。
临床怎么用
- 可考虑采用早期HSFC检测外周血B细胞亚群微小残留病来评估利妥昔单抗药效学和预后,指导难治性炎性肌病的B细胞清除策略优化。
局限性
- 单中心回顾性设计,样本量44例,结论需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rituximab treatment has shown inconclusive results in clinical trials and observational studies in patients with idiopathic inflammatory myopathies. This study aimed to assess whether complete depletion of distinct B-cell subsets was associated with clinical response in rituximab-treated patients with myositis using highly sensitive flow cytometry (HSFC). METHODS: This single-centre, retrospective cohort study included adults (aged ≥18 years) treated with rituximab who fulfilled the American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) classification criteria for idiopathic inflammatory myopathies, followed up at the Leeds Teaching Hospitals NHS Trust (Leeds, UK). HSFC was performed before the first rituximab infusion and at 2 weeks. The primary outcome was a clinical response (at least moderate improvement on the 2016 ACR-EULAR total improvement score) at the first follow-up 4-6 months after infusion. Associations of clinical response with complete HSFC depletion (<0·1 cells per μL) of naive B cells, memory B cells, and plasmablasts versus the conventional flow cytometry cutoff (<5 total B cells per μL) were assessed using multivariable Firth penalised logistic regression. No patients with lived experience were involved in the study. FINDINGS: Between Jan 1, 2015, and Dec 31, 2025, 44 patients with idiopathic inflammatory myopathies were treated with rituximab and had complete datasets. Of these patients, 24 (55%) had dermatomyositis, 12 (27%) had antisynthetase syndrome, five (11%) had immune-mediated necrotising myositis, and three (7%) had polymyositis. 17 (39%) of 44 patients were male, 27 (61%) were female, 35 (80%) were White, and the median age was 45 years (IQR 38-56). Rituximab response occurred in 31 (70%) patients. The total improvement score was higher in responders than non-responders (median 50·0 [IQR 45·0-55·0] vs 17·5 [10·0-30·0]; p<0·0001). At 2 weeks, memory B-cell counts and plasmablast counts were lower in responders than non-responders and complete plasmablast depletion was significantly more frequent in responders (29 [94%] of 31 vs four [31%] of 13; p<0·0001). In multivariable models, higher 2-week plasmablast counts were associated with lower odds of response (odds ratio 0·03 [95% CI 0·00-0·23]), whereas depletion of memory B cells (8·68 [1·13-82·80]) and plasmablasts (25·20 [4·61-214·54]) was associated with response. The conventional flow cytometry cutoff showed no association with response. INTERPRETATION: Complete early B-cell depletion, measured using an early HSFC-based strategy, but not conventional flow cytometry, was associated with rituximab response in patients with idiopathic inflammatory myopathies, supporting further evaluation of a peripheral blood B-cell minimal residual disease framework as a pharmacodynamic and prognostic strategy. These findings could help to select and optimise advanced B-cell depleting strategies in patients with refractory inflammatory myopathies. FUNDING: Leeds National Institute of Health Research Biomedical Research Centre.
引用
- Tonutti A, Trunfio F, Bissell LA, et al. Minimal residual disease flow cytometry of peripheral blood B-cell subsets in patients with idiopathic inflammatory myopathies following rituximab therapy: a single-centre, retrospective cohort study. Lancet Rheumatol. 2026. PMID: 42660164. doi:10.1016/S2665-9913(26)00215-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。